Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: firstname.lastname@example.org. Type 508 Accommodation in the subject line of e-mail.
Implementation of Recommendations for Influenza Control
A symposium, "Options for the Control of Influenza," was organized by CDC and held April 20-25, 1985, in Keystone, Colorado, as part of the 1985 University of California, Los Angeles, Symposia series. The program included a roundtable discussion to consider ways to improve influenza control measures in several populations.* This article summarizes the major viewpoints emerging from that discussion and includes suggestions for expanding the use of influenza vaccine. TARGET GROUPS
Among the topics discussed were improving implementation of the current U.S. Public Health Service (PHS) Immunization Practices Advisory Committee (ACIP) recommendations for prevention and control of influenza among persons in the high-priority groups for annual vaccination (1) and broadening those recommendations to include persons not currently included in the ACIP's high-priority groups.
Children. Morbidity rates during influenza epidemics are often highest among children; children also are believed to have an important role in disseminating infection. Therefore, annual immunization of children who are household contacts of high-risk persons was suggested. For this suggestion to be implemented effectively, cooperation between pediatricians and other physicians providing care for families with high-risk persons must be encouraged. The high-risk groups should be expanded to include children with reactive airway disease.
Healthy Adults. With improved community surveillance and application of rapid diagnostic methods, offering vaccine to healthy adults when an influenza epidemic begins could lessen the impact of the epidemic.
Outbreaks may last 6-8 weeks in an average community. Vaccine may be administered when influenza-like illness is first identified. In addition, during type A epidemics, amantadine can be given to provide protection during the 2-week postvaccination period before effective antibody levels have developed. The following groups of healthy adults should be given special consideration as vaccine candidates during epidemics:
levels recommended by the ACIP will require a sustained vigorous effort. Systematic immunization programs can be incorporated into routine care of high-risk adults. Many high-risk persons could be vaccinated when they encounter health-care providers during the late fall or early winter. High-risk persons who do not require routine follow-up during the year should have special appointments made for the purpose of influenza immunization. Review of patients' immunization status should be routine when patients schedule visits. A uniform adult immunization record card could be developed to provide the patient, physician, and office staff with immediate information about immunization status. The card could be used to document that a patient was offered vaccine at the appropriate time of year. High-risk patients could indicate by signature if they elect not to receive vaccine. This latter practice would reinforce the importance attached to routine immunizations.
Institutionalized High-Risk Adults. Most nursing homes organize programs for annual immunizations, but many of these programs could be improved to reach the ACIP's objective of an 80% vaccination rate. Guidelines could be developed to assist such institutions in implementing immunization programs. Certain mandatory requirements, including the following, could also be considered:
immunization is required. These requirements pose a barrier to immunization of institutionalized adults. The barrier could be removed if permission for annual influenza immunization were obtained when the resident is admitted to the home. Educational materials suitable for staff, residents, and family members are needed. OTHER ISSUES
Research Needs. Additional data are needed to: (1) define the level of immunization necessary to prevent influenza outbreaks through the establishment of "herd immunity"; (2) understand the basis of diminished immune response to, and efficacy of, vaccine in the elderly; (3) monitor the immune status of high-risk persons who are revaccinated annually; and (4) document the costs and benefits of immunization in different groups.
Antiviral Chemotherapy and Chemoprophylaxis. In addition to specific recommendations for using amantadine in therapy and prophylaxis, particularly for high-risk persons (1), amantadine was recommended for all members of households with high-risk persons once a suspected index case of influenza A infection occurs. Improved rapid diagnostic tests would facilitate implementation of this recommendation. The frequency and significance of amantadine-resistant strains should also be evaluated.
Vaccination Costs and Liability. Three complex issues affecting implementation of immunization recommendations were recognized: (1) detection and compensation for vaccine-associated reactions; (2) relative benefits of health-care resources used for prevention of disease, compared with treatment of illness; and (3) current discrepancy between Medicare reimbursement for pneumococcal vaccine and influenza vaccine. Reported by C Wilfert, MD, Duke University School of Medicine, Durham, North Carolina; Influenza Br, Div of Viral Diseases, Center for Infectious Diseases, CDC.
Editorial Note: Influenza epidemics are generally unpredictable in their frequency and severity but normally are associated with increased hospitalizations and mortality among the elderly and persons with certain chronic illnesses (3). For example, surveillance during 1984-1985, when influenza A(H3N2) viruses predominated, demonstrated the highest mortality since 1975-1976, a situation that could not have been anticipated in advance of the epidemic. Over 80% of excess mortality occurs among persons 65 years and older.
The ACIP strongly recommends annual immunization of high-risk persons with inactivated influenza vaccine as the most important way to reduce the impact of influenza. Despite these recommendations, and the apparent benefits of influenza vaccination programs (4,5), the use of inactivated influenza vaccine by high-risk groups remains low, averaging 20% (6), with 55%-60% of residents in U.S. nursing homes receiving vaccine (7).
The suggestions arising from the Keystone symposium are an extension of existing ACIP recommendations and PHS policies. They were developed to assist persons concerned about the occurrence of severe influenza infections, particularly among high-risk patients. Certain general trends appear in the suggestions:
professionals' being convinced that worthwhile reductions in influenza illness and its complications can be achieved, although influenza vaccine does not guarantee protection to each person who receives it.
Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to email@example.com.
Page converted: 08/05/98
This page last reviewed 5/2/01